reason report
remain optimist higher spend support top-lin
growth pt
bottom line top-line guidanc came in-lin expect
includ new launch howev revenu driver
becom lever complex generics/biosimilars/brand
requir higher invest believ notabl expect increas
spend appropri direct support key growth driver
busi remain posit name lower
number reflect higher sg lower margin
greater confid forecast mid-singl digit top-lin growth
achiev especi given unlik past year sale
depend pend signific fda approv revis
estim lower pt continu believ
diversifi portfolio underappreci reiter
op rate said believ stock gain posit
momentum investor like wait see top-lin execut
outcom strateg review appear near complet
chang model rais revenu
primarili due acceler share gain gener copaxon
higher row partial off-set lower sale eu gm lower
increas sg within rang
manag guidanc overal lower ep
ebitda declin
appli unchang ev/ebitda multipl yield new pt
y/i increas sg larger street
expect direct right area support
biosimilars/complex gener portfolio midpoint guidanc
assum y/i increas sg spend support complex
gener portfolio key growth driver busi complex
gener biosimilar global key brand higher level support
necessari support top-lin perform effort includ
comprehens patient support fulphila gener copaxon
dedic sale forc wixela sale forc expans broaden
geographi key brand like creon dona dymista influvac
see eu row geographi grow mid-singl digit
fulphila gotten good start gener copaxon appear
see share gain believ ad spend support
continu perform
continu next page
ev/ebitda multipl
net debt total capit
gener
year price history/av daili volume mil
compani inform svb leerink llc research
revenu
pleas refer page import disclosur price chart analyst certif
morgantown financi impact larg rear view mirror
na busi guidanc high-singl digit growth certainli assum
downward pressur morgantown facil issu
unlik less certain headwind complet
pass lead lower-than-guid y/i growth rate
look perform busi throughout year get
comfort
outcom strateg review appear near complet
continu littl insight rang option
committe assess manag comment suggest review
get close complet
place outperform rate share base strong pipelin biosimilar
durabl ou busi growth off-set continu us base busi
gener eros support revenu growth potenti near-term
upsid consensu number limit competit copaxon advair though
difficult high visibl insulin/biosimilar growth driver could
expand multipl rel peer strong balanc sheet allow
share buy-back smaller bolt-on acquisit expand geograph and/or therapeut
use weight averag ev/ebitda multipl ebitda deriv
price target per share
gener advair opportun may smaller estim commerci uptak
biosimilar may take longer anticip growth ou market may slower
expect market penetr gener copaxon may improv biosimilar neulasta ramp
may slower estim remedi morgantown facil may take longer
allevi reach lower capac current estim
drug producttop indicationev detailsd rangebiosimilar herceptinoncologypotenti us restasisdri eyepotenti segment growth vs digitseu segment growth vs digitsrow segment growth vs digitsadjust gross sg free tax averag number sharesissu
figur chang model
svb leerink estim note number except ep margin
figur chang model continu
svb leerink estim note number except ep margin
note number except ep margin
changevalu changevarianceconsensusactu vs consgeograph areanorth basic dilut non-gaap adjustmentstot one-tim net
number except per share data
net debt ebitda ratio
number except per share data
number except per share data
assum ftf product
gleevec approv launch
restasi assum launch pend approv
lialda launch jan zydu day exclus expir pend approv
advair assum get approv
cubicin assum get approv
ulor settlement june tent approv
treanda assum settlement par ftf date pend approv
norvir/kaletra assum patent expir jan tent approv
tarceva undisclos settlement assum month last patent approv
sutent lost feb patent tent approv
jevtana assum patent expiri pend approv
brilinta assum jul patent expiri pend approv
brevibloc undisclos settlement assum month last patent expiri approv
number except per share data
januvia franchis assum compound patent tent approv
vimpat lost patent expir pend approv
banzel settlement may approv
onglyza franchis lost jul patent pend approv
vyvans lost feb patent tent approv
assum ftf pipelin sub-tot
number except per share data
insulin collabor biocon
biosimilar collabor biocon momenta
ogivri biosim herceptin launch
eylea phase initi us patent protect
number except per share data
number except per share data
number except per share data
number except per share data
prepaid expens current
current portion ltd
number except per share data
adjust reconcil ni net cash oper
litig settlement conting net
loss acquisition-rel foreign currenc deriv
loss equiti method invest
write financ fee
decreas increas work capit
paid acquisit net
purchas properti plant equip capital-expenditure
payment product right net
paid meda uncondit defer payment
settlement acquisition-rel foreign currenc deriv
proce sale asset subsidiari
purchas market secur
chang restrict cash
proce sale market securitin
net invest
payment financ fee
proce convert note hedg
proce issuance/ purchas ordinari share net
proce exercis stock option
tax paid relat net share settlement equiti award
acquisit non-controlling interest
net financ
effect cash chang exchang rate
net chang equival
